Contains Nonbinding Recommendations

Draft Guidance on Tapentadol Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Tapentadol Hydrochloride

Form/Route: Extended Release Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 250 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments: A common approach is to administer 50 mg of naltrexone at the following times: (i) 12 hours prior to dosing, (ii) at the time of study drug dosing, and (iii) 12 hours after the last dose of study drug. Please also consult with a physician who is an expert in the administration of opioids for an appropriate dose of narcotic antagonist.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 250 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments: Please see comment above.

Analytes to measure (in appropriate biological fluid): Tapentadol in plasma

Bioequivalence based on (90% CI): Tapentadol

Waiver request of in-vivo testing: 50 mg, 100 mg, 150 mg, and 200 mg based on (i) acceptable bioequivalence studies on the 250 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.)

Please refer to Mirtazapine Tablet Draft Guidance for additional information regarding waivers of in-vivo testing.

Recommended Jun 2012
Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

In addition to the method above, for modified release products, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer) should be submitted in the application. Agitation speeds may have to be increased if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Please include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.

Due to a concern of dose dumping of drug from this drug product when taken with alcohol, the Agency currently requests that additional dissolution testing be conducted using various concentrations of ethanol in the dissolution medium, as follows:

- **Testing Conditions:** 900 mL, 0.1 N HCl, USP apparatus 2 (paddle) @50 rpm, with or without alcohol;
- **Test 1:** 12 units tested according to the proposed method (with 0.1N HCl), with data collected every 15 minutes for a total of 2 hours
- **Test 2:** 12 units analyzed by substituting 5% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours
- **Test 3:** 12 units analyzed by substituting 20% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours
- **Test 4:** 12 units analyzed by substituting 40% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Both test and RLD products must be tested accordingly and data must be provided on individual unit, means, range and %CV on both strengths.

*Recommended Jun 2012*